Literature DB >> 18614214

Posterior fossa exploration in treatment of trigeminal neuralgia associated with multiple sclerosis.

Branislav Antic1, Predrag Peric.   

Abstract

BACKGROUND: The possible surgical options during PFE in treatment of TN in patients with MS are MVD and PSR. Only sporadic cases of PSR in treatment of TN patients with MS have been reported.
METHODS: We retrospectively analyzed the outcome of surgical treatment in 8 patients with MS who underwent PFE due to surgical treatment of medically intractable TN. MVD was projected in severe neurovascular conflict, MVD + PSR in mild conflict, and PSR alone in cases without neurovascular conflict.
RESULTS: There were no patients with severe neurovascular contact. In 5 patients with mild neurovascular contact and in 3 without neurovascular contact, MVD + PSR and PSR alone were performed, respectively. An immediate BNI-score of I was achieved in all patients. There were 2 minor and 1 major recurrences. Nine years after surgery, 75% of the patients were free of pain. There was no immediate postoperative mortality. Postoperative cerebrospinal fluid rhinorrhea in 1 patient was resolved with spinal drainage. Two patients died during the follow-up period due to the complications of MS.
CONCLUSION: In our experience, MVD + PSR or PSR alone are safe and effective surgical procedures in the management of TN complicating MS. In MVD + PSR patients, PSR seems to play more significant role than MVD in pain relief. Since there were not severe neurovascular conflicts in our patients with MS, MVD alone was never justified.

Entities:  

Mesh:

Year:  2008        PMID: 18614214     DOI: 10.1016/j.surneu.2008.04.033

Source DB:  PubMed          Journal:  Surg Neurol        ISSN: 0090-3019


  1 in total

1.  Factors Influencing Decision-making and Outcome in the Surgical Management of Trigeminal Neuralgia.

Authors:  Mohannad B Ammori; Andrew T King; Rekha Siripurapu; Amit V Herwadkar; Scott A Rutherford
Journal:  J Neurol Surg B Skull Base       Date:  2013-02-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.